NASDAQ OMX

Minerva Neurosciences to Report First Quarter 2016 Financial Results and Business Updates on May 3, 2016

Del

WALTHAM, Mass., 2016-04-26 14:30 CEST (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2016 on Tuesday, May 3, 2016.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. 

The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 74086869.  A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva’s proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which recently completed Phase IIa and Phase Ib clinical trials for insomnia and major depressive disorder (MDD), respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com

         Contact:
         
         William B. Boni
         VP, Investor Relations/
         Corp. Communications
         Minerva Neurosciences, Inc.
         (617) 600-7376

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25Pressemelding

Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging24.10.2017 01:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), is pleased to announce that it has entered into a development and commercialization partnership with Advanced Nuclear Medicine Ingredients SA (ANMI). Under the terms of the agreement, Telix and ANMI will partner to commercialise ANMI's 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a proven technology used to accurately image and stage metastatic prostate cancer, in the US market. Telix will also offer the Kit on a worldwide basis as a companion diagnostic imaging agent to the Company's prostate cancer therapeutic (TLX-591)1. The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisatio

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)23.10.2017 23:00Pressemelding

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million. The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidel

Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast23.10.2017 17:03Pressemelding

Date:    Thursday, November 9, 2017 Time:   11:00 a.m. (Eastern Time)  BROOKFIELD, News, Oct. 23, 2017 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Third Quarter Conference Call & Webcast on Thursday, November 9, 2017 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-800-319-4610 toll free in North America, or for overseas calls please dial 1-604-638-5340 at approximately 10:50 a.m. The Conference Call will also be Webcast live at http://servic

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines23.10.2017 13:00Pressemelding

LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government's responsiveness to future pandemic threats. When combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection system, the rapid sterility test will result in faster release of vaccines and other sterile products. Timely delivery of these products carries multiple public benefits, principally in facilitating rapid responses to pandemic or emerging infections, agents of bioterrorism, and availability of life saving medicines. "Our continuing relationship with BARDA demonstrate

Xehar Fashion App Ditches the Shopping Cart and Picks Up Speed23.10.2017 12:00Pressemelding

New fast fashion app will shorten the checkout time by removing the shopping cart altogether. PLAYA VISTA, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Fashion tech company Xehar, today announces they will be removing the shopping cart from their Xehar shopping app. For millennial women shoppers who are interested in fashion but are frustrated with the online shopping experience, the Xehar app is their solution. "Xehar has found a way to increase conversion for app purchases by simply removing the function of the shopping cart," says Hadari Oshri, founder and CEO of Xehar. "Within the app, users select complete outfits and purchase with ease. By removing the shopping cart we are reducing friction and speeding up the checkout process." A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c58ce496-70e7-4675-8f59-3e39725708c4 Website and app owners deal with the reality of shopping cart abandonment

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom